Log in

TSE:APSAptose Biosciences Stock Price, Forecast & News

C$9.47
+0.06 (+0.64 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
C$9.10
Now: C$9.47
C$9.69
50-Day Range
C$9.41
MA: C$10.68
C$12.07
52-Week Range
C$2.37
Now: C$9.47
C$12.62
Volume77,600 shs
Average Volume98,952 shs
Market CapitalizationC$722.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-647-4799828

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$1.08 per share
Book ValueC$1.14 per share

Profitability

Miscellaneous

Employees31
Market CapC$722.31 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive APS News and Ratings via Email

Sign-up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

Aptose Biosciences (TSE:APS) Frequently Asked Questions

How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Aptose Biosciences' stock was trading at C$7.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APS stock has increased by 19.4% and is now trading at C$9.47. View which stocks have been most impacted by Coronavirus.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (TSE:APS) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.06. View Aptose Biosciences' earnings history.

Has Aptose Biosciences been receiving favorable news coverage?

Press coverage about APS stock has been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptose Biosciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutAptose Biosciences.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), Altagas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."

How do I buy shares of Aptose Biosciences?

Shares of APS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APS stock can currently be purchased for approximately C$9.47.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of C$722.31 million. Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is aptose.com.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company can be reached via phone at +1-647-4799828.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.